Non-small-cell lung carcinoma vaccines in clinical trials

References

• Higano CS, Schellhammer PF, Small EJ et al. Integrated data from 2 randomized, double-blind, placebo controlled, Phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer115(16), 3670–3679 (2009).
   PubMed Web of Science ®Google Scholar
• Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl Cancer Inst.92(3), 205–216 (2000).
   PubMed Web of Science ®Google Scholar
• Therasse P, Eisenhauer EA, Verweij J. RECIST revisited: a review of validation studies on tumour assessment. Eur. J. Cancer42(8), 1031–1039 (2006).
   PubMed Web of Science ®Google Scholar
• Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Haematol.19(3), 183–232 (1995).
   PubMed Web of Science ®Google Scholar
• Gonzales G, Crombet T, Catala M et al. A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: report of a pilot clinical trial. Ann. Oncol.9(4), 431–435 (1998).
   PubMedGoogle Scholar
• Gonzalez G, Crombet T, Torres F et al. Epidermal growth factor-based cancer vaccine for non-small-cell lung cancer therapy. Ann. Oncol.14(3), 461–466 (2003).
   PubMed Web of Science ®Google Scholar
• Ramos TC, Vinageras EN, Ferrer MC et al. Treatment of NSCLC patients with an EGF-based cancer vaccine: report of a Phase I trial. Cancer Biol. Ther.5(2), 145–149 (2006).
   PubMed Web of Science ®Google Scholar
• Gonzalez G, Crombet T, Neninger E, Viada C, Lage A. Therapeutic vaccination with epidermal growth factor (EGF) in advanced lung cancer: analysis of pooled data from three clinical trials. Hum. Vaccin.3(1), 8–13 (2007).
   PubMed Web of Science ®Google Scholar
• Neninger E, Verdegia BG, Crombet T et al. Combining an EGF-based cancer vaccine with chemotherapy in advanced nonsmall cell lung cancer. J. Immunother.32(1), 92–99 (2009).
   PubMed Web of Science ®Google Scholar
• Garcia B, Neninger E, de la Torre A et al. Effective inhibition of the epidermal growth factor/epidermal growth factor receptor binding by anti-epidermal growth factor antibodies is related to better survival in advanced non-small-cell lung cancer patients treated with the epidermal growth factor cancer vaccine. Clin. Cancer Res.14(3), 840–846 (2008).
   PubMed Web of Science ®Google Scholar
• Neninger Vinageras E, de la Torre A, Osorio Rodriquez M et al. Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer. J. Clin. Oncol.26(9), 1452–1458 (2008).
   PubMed Web of Science ®Google Scholar
• Grange JM, Bottasso O, Stanford CA, Stanford JL. The use of mycobacterial adjuvant-based agents for immunotherapy of cancer. Vaccine26(39), 4984–4990 (2008).
   PubMedGoogle Scholar
• O’Brien ME, Saini A, Smith IE et al. A randomized Phase II study of SRL172 (Mycobacterium vaccae) combined with chemotherapy in patients with advanced inoperable non-small-cell lung cancer and mesothelioma. Br. J. Cancer83(7), 853–857 (2000).
   PubMedGoogle Scholar
• O’Brien ME, Anderson H, Kaukel E et al. SRL172 (killed Mycobacterium vaccae) in addition to standard chemotherapy improves quality of life without affecting survival, in patients with advanced non-small-cell lung cancer: Phase III results. Ann. Oncol.15(6), 906–914 (2004).
   PubMed Web of Science ®Google Scholar
• Stanford JL, Stanford CA, O’Brien ME, Grange JM. Successful immunotherapy with Mycobacterium vaccae in the treatment of adenocarcinoma of the lung. Eur. J. Cancer44(2), 224–227 (2008).
   PubMed Web of Science ®Google Scholar
• Gupta K, Cooper C. A review of the role of CpG oligodeoxynucleotides as Toll-like receptor 9 agonists in prophylactic and therapeutic vaccine development in infectious diseases. Drugs R. D.9(3), 137–145 (2008).
   PubMed Web of Science ®Google Scholar
• Weeratna RD, Bourne LL, Sullivan SM et al. Combination of a new TLR9 agonist immunomodulator (CpG 7909) and paclitaxel for treatment of metastatic Lewis lung carcinoma (LLC). Presented at: 40th American Society of Clinical Oncology. New Orleans, LA, USA, 5–8 June 2004.
   Google Scholar
• Yamada K, Nakao M, Fukuyama C et al. Phase I study of TLR9 agonist PF-3512676 in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer. Cancer Sci.101(1), 188–195 (2010).
   PubMedGoogle Scholar
• Manegold C, Gravenor D, Woytowitz D et al. Randomized Phase II trial of a Toll-like receptor 9 agonist oligodeoxynucleotide, PF-3512676, in combination with first-line taxane plus platinum chemotherapy for advanced-stage non-small-cell lung cancer. J. Clin. Oncol.26(24), 3979–3986 (2008).
   PubMed Web of Science ®Google Scholar
• Hirsh V, Boyer M, Rosell R et al. Randomized Phase III trial of paclitaxel/carboplatin with or without PF-3512676 as first line treatment of advanced non-small cell lung cancer (NSCLC). Presented at: 44th American Society of Clinical Oncology. Chicago, IL, USA, 30 May–3 June 2008.
   Google Scholar
• Manegold C, Thatcher N, Benner RJ et al. Randomized Phase III trial of gemcitabine/cisplatin with or without PF-3512676 as first line treatment of advanced non-small cell lung cancer (NSCLC). Presented at: 44th American Society of Clinical Oncology. Chicago, IL, USA, 30 May–3 June 2008.
   Google Scholar
• Peat N, Gendler SJ, Lalani N, Duig T, Taylor-Papadimitriou J. Tissue-specific expression of a human polymorphic epithelial mucin (MUC1) in transgenic mice. Cancer Res.52(7), 1954–1960 (1992).
   PubMed Web of Science ®Google Scholar
• Vlad AM, Kettel JC, Alajez NM, Carlos CA, Finn OJ. MUC1 immunobiology: from discovery to clinical applications. Adv. Immunol.82, 249–293 (2004).
   PubMed Web of Science ®Google Scholar
• Rochlitz C, Figlin R, Squiban P et al. Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer. J. Gene Med.5(8), 690–699 (2003).
   PubMed Web of Science ®Google Scholar
• Agrawal B, Krantz MJ, Reddish MA, Longenecker BM. Rapid induction of primary human CD4+ and CD8+ T cell responses against cancer-associated MUC1 peptide epitome. Int. Immunol.10(12), 1907–1916 (1998).
   PubMed Web of Science ®Google Scholar
• North S, Butts C. Vaccination with BLP25 liposome vaccine to treat non-small cell lung cancer and prostate cancers. Expert Rev. Vaccines4(3), 249–257 (2005).
   PubMed Web of Science ®Google Scholar
• Palmer M, Parker J, Modi S et al. Phase I study of the BLP25 (MUC1 peptide) liposomal vaccine for active specific immunotherapy in stage IIIB/IV non-small-cell lung cancer. Clin. Lung Cancer3(1), 49–57 (2001).
   PubMedGoogle Scholar
• Butts C, Murray N, Maksymiuk A et al. Randomized Phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J. Clin. Oncol.23(27), 6674–6681 (2005).
   PubMed Web of Science ®Google Scholar
• Butts C, Anderson H, Maksymiuk A et al. Long-term safety of BLP25 liposome vaccine (L-BLP25) in patients (pts) with stage IIB/IV non-small cell lung cancer (NSCLC). Presented at: 45th American Society of Clinical Oncology. Orlando, FL, USA, 29 May–2 June 2009.
   Google Scholar
• Butts C, Murray RN, Smith CJ et al. A multicenter open-label study to assess the safety of a new formulation of BLP25 liposome vaccine in patients with unresectable stage III non-small-cell lung cancer. Clin. Lung Cancer11(6), 391–395 (2010).
   PubMedGoogle Scholar
• Butts C, Maksymiuk A, Goss G et al. A multi-centre Phase IIB randomized controlled study of BLP25 liposome vaccine (L-BLP25 or Stimuvax) for active specific immunotherapy of non-small cell lung cancer (NSCLC): updated survival analysis. Presented at: 12th World Conference on Lung Cancer. Seoul, Korea, 2–6 September 2007.
   Google Scholar
• Malykh YN, Schauer R, Shaw L. N-glycolylneuraminic acid in human tumours. Biochimie83(7), 623–634 (2001).
   PubMed Web of Science ®Google Scholar
• Ramlau R, Quoix E, Rolski J et al. A Phase II study of TG4010 (MVA-MUC1-IL2) in association with chemotherapy in patients with stage III/IV non-small cell lung cancer. J. Thorac. Oncol.3(7), 735–744 (2008).
   PubMed Web of Science ®Google Scholar
• Ramlau R, Westeel V, Papai Z et al. Randomized Phase IIb trial evaluating the therapeutic vaccine TG4010 (MVA-MUC1-IL2) as an adjunct to chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). Presented at: 44th American Society of Clinical Oncology. Chicago, IL, USA, 30 May–3 June 2008.
   Google Scholar
• Kong F, Jirtle RL, Huang DH, Clough RW, Anscher MS. Plasma transforming growth factor-β1 level before radiotherapy correlates with long term outcome of patients with lung carcinoma. Cancer86(9), 1712–1719 (1999).
   PubMed Web of Science ®Google Scholar
• Nemunaitis J, Dillman RO, Schwarzenberger PO et al. Phase II study of belagenpumatucel-L, a transforming growth factor β2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. J. Clin. Oncol.24(29), 4721–4730 (2006).
   PubMed Web of Science ®Google Scholar
• Nemunaitis J, Nemunaitis M, Senzer N et al. Phase II trial of belagenpumatucel-L, a TGF-β2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients. Cancer Gene Ther.16(8), 620–624 (2009).
   PubMed Web of Science ®Google Scholar
• Sienel W, Varwerk C, Linder A et al. Melanoma associated antigen (MAGE)-A3 expression in stages I and II non-small cell lung cancer: results of a multi-center study. Eur. J. Cardiothorac. Surg.25(1), 131–134 (2004).
   PubMed Web of Science ®Google Scholar
• Gaugler B, Van den Eynde B, van der Bruggen P et al. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J. Exp. Med.179(3), 921–930 (1994).
   PubMed Web of Science ®Google Scholar
• Vansteenkiste J, Zielinski M, Linder A et al. Final results of a multi-center, double-blind, randomized, placebo-controlled Phase II study to assess the efficacy of MAGE-A3 immunotherapeutic as adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC). Presented at: 43rd American Society of Clinical Oncology. Chicago, IL, USA, 1–5 June 2007.
   Google Scholar
• Vansteenkiste J, Zielinski M, Dahabreh IJ et al. Association of gene expression signature and clinical efficacy of MAGE-A3 antigen-specific cancer immunotherapeutic (ASCI) as adjuvant therapy in resected stage IB/II non-small cell lung cancer (NSCLC). Presented at: 44th American Society of Clinical Oncology. Chicago, IL, USA, 30 May–3 June 2008.
   Google Scholar
• Tyagi P, Mirakhur B. MAGRIT: the largest-ever Phase III lung cancer trial aims to establish a novel tumor-specific approach to therapy. Clin. Lung Cancer10(5), 371–374 (2009).
   PubMed Web of Science ®Google Scholar
• Vazquez AM, Gabri MR, Hernandez AM et al. Antitumor properties of an anti-idiotypic monoclonal antibody in relation to N-glycolyl-containing gangliosides. Oncol. Rep.7(4), 751–756 (2000).
   PubMed Web of Science ®Google Scholar
• Fernandez LE, Gabri MR, Guthmann MD et al. NGcGM3 ganglioside: a privileged target for cancer vaccines. Clin. Dev. Immunol. DOI: 10.1155/2010/814397 (2010) (Epub ahead of print).
   PubMedGoogle Scholar
• Alfonso S, Diaz RM, de la Torre A et al. 1E10 anti-idiotype vaccine in non-small cell lung cancer. Cancer Biol. Ther.6(12), 1847–1852 (2007).
   PubMed Web of Science ®Google Scholar
• Hernandez AM, Toledo D, Martinez D et al. Characterization of the antibody response against NeuGcGM3 ganglioside elicited in non-small cell lung cancer patients immunized with an anti-idiotype antibody. J. Immunol.181(9), 6625–6634 (2008).
   PubMed Web of Science ®Google Scholar
• Cheever MA, Allison JP, Ferris AS et al. The prioritization of cancer antigens: a National Cancer Institute pilot project for the acceleration of translational research. Clin. Cancer. Res.15(17), 5323–5337 (2009).
   PubMed Web of Science ®Google Scholar